Multiple Myeloma Treatments

Below is a listing of treatments for multiple myeloma that are being tested in clinical trials around the US. We're here if you have questions or need help. Please call us today or create an account and we'll help you better understand your clinical trial options.

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

Daratumumab DARZALEX®

Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.

Learn more about this treatment


Nivolumab

Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Learn more about this treatment


Ipilimumab

Ipilimumab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


RO6870810

RO6870810 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called Bromodomain and Extra-Terminal Protein (BET) Inhibitors.

Learn more about this treatment


T Cells

A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.

Learn more about this treatment


Selinexor

Selinexor is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.

Learn more about this treatment


GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).

Learn more about this treatment


SEA-BCMA

SEA-BCMA is a new antibody targeting the BCMA protein and being tested in multiple myeloma.

Learn more about this treatment


Bortezomib VELCADE®

Bortezomib is used to treat multiple myeloma and mantle cell lymphoma. It is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Bortezomib is given as an injection under the skin (subcutaneously) or injected into a vein through an IV.

Learn more about this treatment


Atezolizumab

Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.

Learn more about this treatment


Checkpoint Inhibitor

Immune checkpoint inhibitors are drugs – often made of antibodies – that unleash an immune system attack on cancer cells.

Learn more about these treatments


Venetoclax

ABT-199 is an anti-apoptotic protein Bcl-2 inhibitor that mimics BH3-only proteins, the native ligands of Bcl-2 and programmed cell death activators, repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.

Learn more about this treatment


Carfilzomib KYPROLIS®

Carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is approved for use with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma in patients who have received one to three prior lines of therapy. Carfilzomib is injected into a vein through an IV.

Learn more about this treatment


Melflufen

Melflufen is a modified version of the chemotherapy drug melphalan that is being investigated as a treatment for myeloma.

Learn more about this treatment


Cetuximab

Cetuximab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat colorectal cancer and squamous cell carcinoma of the head and neck. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


SGN-CD48A

SGN-CD48A is a novel humanized anti-cd48 antibody-drug conjugate being tested for the treatment of multiple myeloma.

Learn more about this treatment


Temsirolimus

Temsirolimus is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat renal cell carcinoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


Ixazomib NINLARO®

Ixazomib is an oral proteasome inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Learn more about this treatment


PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

Learn more about this treatment


Autologous Transplant

Autologous Transplant is a type of stem cell transplant that utilizes the patient's pre-collected own stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.

Learn more about this treatment


bb2121

bb2121 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb2121 removes and destroys them.

Learn more about this treatment


Monoclonal Antibody

Antibodies are cloned and used to attack one specific type of protein found in cancer cells.

Learn more about these treatments


Allogeneic Transplant

Allogeneic Transplant is a type of stem cell transplant that utilizes a donor (not from own) pre-collected stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.

Learn more about this treatment


Abemaciclib VERZENIO

Abemaciclib is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. It is also being tested in other cancers including myeloma.

Learn more about this treatment


BION-1301

BION-1301 is a humanized antibody that blocks A PRoliferation-Inducing Ligand (APRIL) from binding to its receptors, using Aduro’s B-select monoclonal antibody platform. In preclinical studies, BION-1301 eliminated malignant cells and reduced resistance to therapy in models of multiple myeloma.

Learn more about this treatment


Elotuzumab EMPLICITI®

Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.

Learn more about this treatment


Lenalidomide REVLIMID®

Lenalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is given as an oral medication.

Learn more about this treatment


Panobinostat FARYDAK®

Panobinostat is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It has been approved to be used in combination with bortezomib and dexamethasone to treat people with multiple myeloma who have received at least two other standard treatments (including bortezomib and an immunomodulating agent).

Learn more about this treatment


CLR 131

CLR 131 is an investigational compound under development for a range of hematologic malignancies. It is currently being evaluated in a Phase I and Phase II clinical trial in patients with relapsed or refractory hematological diseases.

Learn more about this treatment


Dabrafenib

Dabrafenib is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


ONC201

ONC201 is a first in class anti tumor drug that can work by producing stress chemicals in the cancer cell and blocking it from growing and dividing.

Learn more about this treatment


Trametinib

Trametinib is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


ABC294640

ABC294640 is a new drug being investigated as a treatment for myeloma. It is administered orally and has anti-cancer and anti-inflammatory activities.

Learn more about this treatment


INCB053914

INCB053914 is a pan-PIM inhibitor that can work by blocking specific chemicals in the cancer cell that block some cells from dividing and growing.

Learn more about this treatment


Natural Killer (NK) Cells

Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).

Learn more about this treatment


CC-220

CC-220 is a Cereblon (CRBN) binding compound currently under clinical investigation for multiple myeloma.

Learn more about this treatment


Denosumab

Denosumab is a humanized monoclonal antibody that binds to RANKL and blocks the interaction of RANKL with RANK, resulting in inhibition of bone destroying cells and a decrease in bone breakdown.

Learn more about this treatment


Dendritic Cell Fusion Vaccine

Dendritic Cell Fusion Vaccines are a type of immunotherapy where our own cells, in this case, dendritic cells, are loaded with tumor antigens to help the immune system recognize and mount a response to those cancer cells present in the body.

Learn more about this treatment


TAK-079

TAK-079 is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.

Learn more about this treatment


Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

Learn more about this treatment


Isatuximab

SAR650984 is a humanized IgG1 monoclonal antibody that binds to CD38+ cells, triggerring antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and tumor programmed cell death.

Learn more about this treatment


AMG 176

AMG 176 is an MCL-1 inhibitor (myeloid cell leukemia-1) that can prevent cancer cells from creating proteins to protect itself, and can cause cell death.

Learn more about this treatment


Adoptive Cellular Therapy

In adoptive cellular therapy, T cells are removed from a patient, genetically modified or treated with chemicals to enhance their activity, and then re-introduced into the patient with the goal of improving the immune system's anti-cancer response.

Learn more about these treatments


Antibody Drug Conjugates

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

Learn more about these treatments


Pembrolizumab

One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.

Learn more about this treatment


Immunotherapy

Immunotherapy involves the use of many active agents such as cells, cytokines or vaccines (among others). These agents are used to induce, enhance or suppress the function of the immune system.

Learn more about these treatments


Bendamustine

Bendamustine is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


Busulfan

Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat chronic myelogenous leukemia (CML). It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


Ibrutinib

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.

Learn more about this treatment


Measles Virus

Cancer treatment with the Measles Virus can work by modifying the virus to only infect cancer cells. Once injected into the body, the virus then can seek out and kill the cancer cells.

Learn more about this treatment


Sotatercept

Sotatercept binds to activin, inhibiting its binding to ActRIIA and ActRIIA signaling, resulting in the stimulation of bone building activity and the inhibition of bone destroying activity, resulting in bone formation and increased bone mineral density and strength.

Learn more about this treatment


TTI-621

TTI-621 is a novel checkpoint inhibitor of the innate immune system, in relapsed or refractory hematologic malignancies.

Learn more about this treatment


Stem Cell Transplants

Stem cell transplants use a patient's own stem cells (autologous) or those from a donor (allogeneic) to rescue the bone marrow from the intense effects of high dose of chemotherapy.

Learn more about these treatments


AZD5991

AZD5991 is an Mcl-1 inhibitor being tested in multiple myeloma.

Learn more about this treatment


TEW-7197

TEW-7197 is a small molecule TGF-β type I receptor kinase inhibitor.

Learn more about this treatment


MEDI7247

An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.

Learn more about this treatment


Lintuzumab AC 225

Lintuzumab AC 225 is an Antibody Radio-Conjugate (ARC) comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the radioisotope actinium-225.

Learn more about this treatment


Bruton's Tyrosine Kinase (BTK) Inhibitor

Brutons Tyrosine Kinase Inhibitors can block the cancer cell from growing and dividing by stopping messages from being passed by chemicals within the cell.

Learn more about these treatments


Everolimus

Everolimus is approved to treat breast cancer, pancreatic cancer, and renal cell carcinoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


Histone Deacetylase (HDAC) Inhibitor

HDAC Inhibitors can block proteins that tell the cancer cell to grow and divide, which can cause cell death.

Learn more about these treatments


JNJ-68284528

JNJ-68284528 (LCAR-B38M) is an autologous CAR-T therapy that targets B-Cell Maturation Antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The investigational therapy expresses an identical CAR protein as Legend's LCAR-B38M CAR-T product, which was evaluated in a first-in-human clinical study (Legend-2) conducted in multiple sites by Legend Biotech in China.

Learn more about this treatment


bb21217

bb21217 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily.

Learn more about this treatment


Vaccines

Cancer vaccines are designed to stimulate an immune response against tumor-specific or tumor-associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Learn more about these treatments


P-BCMA-101

P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a "safety switch" gene to allow the cells to be eliminated if desired.

Learn more about this treatment


BFCR4350A

BFCR4350A is a bispecific T-cell engager (BiTE) antibody. It targets both the the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and as well as the CD3 antigen found on T lymphocytes.

Learn more about this treatment


JNJ-64007957

JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.

Learn more about this treatment


Immunomodulatory Drugs (IMID)

Immunomodulatory therapies typically involve special chemicals called cytokines. These therapies are designed to enhance the immune system to fight cancer.

Learn more about these treatments


GSK525762

GSK525762 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as BET Inhibitors.

Learn more about this treatment


Bispecific Antibody

A bispecific antibody is a drug that has been designed to simultaneously target two different antigens. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells. This approach gives additional options in targeted immunotherapy and may help the immune system find and kill the cancer cells.

Learn more about these treatments


AMG 701

AMG 701 is a bispecific antibody that targets both CD-3 and BCMA that is being tested in multiple myeloma.

Learn more about this treatment


SurVaxM

SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumor growth and recurrence.

Learn more about this treatment


LY3039478

LY3039478 is a small molecule Gamma-Secretase Inhibitor being investigated in clinical trials in patients with T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma and multiple myeloma.

Learn more about this treatment


Survivin Vaccine

Survivin Vaccine can work by stimulating the immune system to create T-Cells that recognize and attack Survivin, a tumor antigen.

Learn more about this treatment


Pneumococcal 13-Valent Conjugate Vaccine

Prevnar 13 is a vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae for the prevention of pneumococcal disease in immunocompromised patients with cancer.

Learn more about this treatment


INCB057643

INCB057643 is a BET inhibitor that can work by stopping chemicals in the cancer cell that tell it to grow and divide.

Learn more about this treatment


Trivalent Influenza Vaccine

Trivalent Influenza Vaccine is an annually formulated vaccine that contains the three strains of influenza projected to be prevalent in the coming season.

Learn more about this treatment


Reolysin

Reolysin is a serotype 3 Dearing strain (T3D) of reovirus that replicates and induces programmed tumor cell death in RAS-activated tumor cells.

Learn more about this treatment


PF-06863135

PF-06863135 is a B-cell Maturation Antigen (Bcma)-cd3 bispecific antibody being tested in multiple myeloma.

Learn more about this treatment


Nelfinavir VIRACEPT

Nelfinavir is an orally admin­istered drug that belongs to a treatment classification called protease inhibitors. Preclinical data suggests that Nelfinavir may overcome resistance to proteasome inhibitors in multiple myeloma.

Learn more about this treatment


MEDI2228

MEDI2228 is a novel antibody drug conjugate that targets BCMA.

Learn more about this treatment


JNJ-64407564

JNJ-64407564 is a bispecific monoclonal antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.

Learn more about this treatment


JCARH125

JCARH125 is a CAR T-cell product that targets B-cell maturation antigen (BCMA).

Learn more about this treatment


CPI-0610

CPI-0610 inhibits Bromodomain and Extra-Terminal (BET) family of proteins, disrupting chromatin remodeling and gene expression that eventually lead to inhibition of cancer cell growth.

Learn more about this treatment


INCB054828

INCB054828 is an FGFR inhibitor that can work by blocking specific chemicals in the cancer cell that tell help it to grow and divide rapidly.

Learn more about this treatment


BL-8040

BL-8040 is a novel CXC4 antagonist that blocks chemicals in the cancer cell responsible for growth and division and blood vessel development.

Learn more about this treatment


ACP-196

ACP 196 is a new drug being investigated as a treatment for myeloma that belongs to a class of drugs known as bruton tyrosine kinase inhibitors.

Learn more about this treatment


ACP-319

ACP-319 is an orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. PI3K inhibitor ACP-319 inhibits PI3K, which prevents the activation of the PI3K/AKT (protein kinase B)-mediated signaling pathway. This results in the inhibition of growth and survival of PI3K-overexpressing tumor cells.

Learn more about this treatment


AMG 224

AMG-224 is a new drug being tested in myeloma called an antibody-drug conjugate comprised of anti-BCMA–MCC–DM1. It consists of a chemotherapy drug combined with a monoclonal antibody which helps to deliver the drug to myeloma cells.

Learn more about this treatment


AMG 420

AMG 420 is made using Amgen’s proprietary BiTE or “bispecific T-cell engager” technology. AMG 420 consists of two proteins fused together, each designed to interact with a specific target — in this case, BCMA and CD3, a protein found on the surface of T-cells.

Learn more about this treatment


Azacitidine

Azacitidine is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat myelodysplastic syndromes (MDS). It is also being studied in the treatment of other types of cancers, including multiple myeloma.

Learn more about this treatment


BAY1251152

BAY 1251152 is currently being evaluated in Phase I studies to determine the safety, tolerability, pharmacokinetics and initial pharmacodynamic biomarker response in patients with advanced cancer.

Learn more about this treatment


CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. CAR2 Anti-CD38 A2 CAR-T Cells are being evaluated in multiple myeloma (MM) and has successfully demonstrated strong preclinical anti-tumor activity in animal models.

Learn more about this treatment


INCB052793

INCB052793 is a JAK1 inhibitor that can work by blocking chemicals in the cancer cell that are responsible for rapid cell growth and division.

Learn more about this treatment


CC-122

CC-122 is a first in class pleiotropic pathway modulator that binds the special protein complexes in the cell, leading to anti-proliferation of cancer cells and improved immune system functions against cancer cell growth.

Learn more about this treatment


CC-486

CC-486 is an oral azacitidine that is metabolized to 5-azadeoxycitidine triphosphate and reversibly inhibits DNA methyltransferase and blocks DNA methylation leading to cancer cell death.

Learn more about this treatment


CC-93269

CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.

Learn more about this treatment


Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Learn more about this treatment


Durvalumab

Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to strengthen the patient's immune system and attack the cancer.

Learn more about this treatment


INCB039110

INCB039110 is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity that is being tested in multiple myeloma.

Learn more about this treatment


INCB050465

INCB050465 is a PI3K-delta inhibitor that can work by blocking chemicals in the cancer cell that are responsible for growth and division, and by sometimes inducing cell death.

Learn more about this treatment


Proteasome Inhibitor

Proteasome Inhibitors can block cancer cells from removing defective proteins, which can lead to cell death.

Learn more about these treatments

;